8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
Published . Updated .
Key takeaways
- 8-K - Neumora Therapeutics filed an 8-K with the SEC on Nov 16 (a notice of a material company event).
- Exposed: NMRA
- Market reaction: price tracking starts with the next trading session.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Neumora Therapeutics filed an 8-K with the SEC on Nov 16 (a notice of a material company event).
Directly affected
- NMRA Neumora Therapeutics-7.0% 12d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Neumora Therapeutics belongs to, so it often moves with news about it.
- AMGN Amgen+15.9% 30d
Amgen is a peer of Neumora Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+16.4% 30d
Gilead Sciences is a peer of Neumora Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- MRNA Moderna+22.4% 30d
Moderna is a peer of Neumora Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- ARGX argenx SE-11.9% 9d
argenx SE is a peer of Neumora Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- RVMD Revolution Medicines
Revolution Medicines is a peer of Neumora Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| NMRA | +13.57% | +9.58% | base | after close | after close | after close | after close |
| XLV | -0.28% | +0.04% | base | after close | after close | after close | after close |
| AMGN | -0.08% | +0.56% | base | after close | after close | after close | after close |
| GILD | +0.80% | +0.98% | base | after close | after close | after close | after close |
| MRNA | +20.51% | +11.41% | base | after close | after close | after close | after close |
| ARGX | +0.34% | +1.85% | base | after close | after close | after close | after close |
| RVMD | +16.24% | +4.86% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-16 AccNo: 0001193125-26-462165 Size: 355 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Price since this story was published: Neumora Therapeutics (NMRA)
| Company | When | Move | Status |
|---|---|---|---|
| AMGN | three days earlier | +0.56% | final price |
| AMGN | five days earlier | -0.08% | final price |
| ARGX | three days earlier | +1.85% | final price |
| ARGX | five days earlier | +0.34% | final price |
| GILD | three days earlier | +0.98% | final price |
| GILD | five days earlier | +0.80% | final price |
| MRNA | three days earlier | +11.41% | final price |
| MRNA | five days earlier | +20.51% | final price |
| Neumora Therapeutics (NMRA) | three days earlier | +9.58% | final price |
| Neumora Therapeutics (NMRA) | five days earlier | +13.57% | final price |
| RVMD | three days earlier | +4.86% | final price |
| RVMD | five days earlier | +16.24% | final price |
| XLV | three days earlier | +0.04% | final price |
| XLV | five days earlier | -0.28% | final price |
Congressional trades in the stocks in this story
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 3 Nov 2026. That is 13 days before publication. Filed 12 Nov 2026. View the filing.
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $15,001 - $50,000 on 15 Oct 2026. That is 32 days before publication. Filed 2 Nov 2026. View the filing.
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 55 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Moderna (MRNA), worth $1,001 - $15,000 on 20 Oct 2026. That is 27 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 53 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 73 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Argenx Se (ARGX), worth $1,001 - $15,000 on 27 Oct 2026. That is 20 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Argenx Se (ARGX), worth $1,001 - $15,000 on 15 Oct 2026. That is 32 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Argenx Se (ARGX), worth $15,001 - $50,000 on 14 Oct 2026. That is 33 days before publication. Filed 10 Nov 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Neumora Therapeutics (NMRA)
Companies tied to this story
- NMRA Neumora Therapeutics
In “8-K - Neumora Therapeutics, Inc. (0001885522) (Filer),” Neumora Therapeutics (NMRA) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> NMRA
How “8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)” reaches Neumora Therapeutics (NMRA)
The 16 Nov 2026 story “8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)” names Neumora Therapeutics (NMRA) because of this story.
For Neumora Therapeutics (NMRA), the reason on file says SEC 8-K filing -> direct issuer disclosure -> NMRA
Dates and price levels for Neumora Therapeutics (NMRA)
NMRA traded between 0.35 and 0.64 across 12 sessions. The latest close on file is 0.44.
A simple score for Neumora Therapeutics (NMRA)
14 out of 100
“8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.